{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:53:48Z","timestamp":1790621628686,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/gt.2016.36","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T14:41:28Z","timestamp":1460731288000},"page":"606-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Development of an AAV9 coding for a 3XFLAG-TALEfrat#8-VP64 able to increase in vivo the human frataxin in YG8R mice"],"prefix":"10.1038","volume":"23","author":[{"given":"P","family":"Chapdelaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Cherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"Ouellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Jauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"BFgt201636_CR1","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1038\/mtna.2013.41","volume":"2","author":"P Chapdelaine","year":"2013","unstructured":"Chapdelaine P, Coulombe Z, Chikh A, Gerard C, Tremblay JP . A potential new therapeutic approach for Friedreich ataxia: induction of frataxin expression with TALE proteins. Mol Ther Nucleic acids 2013; 2: e119.","journal-title":"Mol Ther Nucleic acids"},{"key":"BFgt201636_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-800563-7.00003-8","volume-title":"Translating Gene Therapy to the Clinic Techniques and Approaches","author":"PI Thakore","year":"2015","unstructured":"Thakore P I, Gersbach CA . Genome engineering for therapeutic applications. In: Laurence J, Frankling M (ed). Translating Gene Therapy to the Clinic Techniques and Approaches. Academic Press: London, UK, 2015, pp 27\u201339."},{"key":"BFgt201636_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev-phyto-080508-081936","volume":"48","author":"J Boch","year":"2010","unstructured":"Boch J, Bonas U . Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu Rev Phytopathol 2010; 48: 419\u2013436.","journal-title":"Annu Rev Phytopathol"},{"key":"BFgt201636_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.pbi.2010.04.010","volume":"13","author":"AJ Bogdanove","year":"2010","unstructured":"Bogdanove AJ, Schornack S, Lahaye T . TAL effectors: finding plant genes for disease and defense. Current opinion in plant biology 2010; 13: 394\u2013401.","journal-title":"Current opinion in plant biology"},{"key":"BFgt201636_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1126\/science.1216211","volume":"335","author":"AN Mak","year":"2012","unstructured":"Mak AN, Bradley P, Cernadas RA, Bogdanove AJ, Stoddard BL . The crystal structure of TAL effector PthXo1 bound to its DNA target. Science 2012; 335: 716\u2013719.","journal-title":"Science"},{"key":"BFgt201636_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1126\/science.1215670","volume":"335","author":"D Deng","year":"2012","unstructured":"Deng D, Yan C, Pan X, Mahfouz M, Wang J, Zhu JK et al. Structural basis for sequence-specific recognition of DNA by TAL effectors. Science 2012; 335: 720\u2013723.","journal-title":"Science"},{"key":"BFgt201636_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nbt.1775","volume":"29","author":"F Zhang","year":"2011","unstructured":"Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P . Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011; 29: 149\u2013154.","journal-title":"Nat Biotechnol"},{"key":"BFgt201636_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF III . ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol 2013; 31: 397\u2013405.","journal-title":"Trends Biotechnol"},{"key":"BFgt201636_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nbt1353","volume":"25","author":"A Lombardo","year":"2007","unstructured":"Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee Y-L, Kim KA et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298\u20131306.","journal-title":"Nat Biotechnol"},{"key":"BFgt201636_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature10177","volume":"475","author":"H Li","year":"2011","unstructured":"Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475: 217\u2013221.","journal-title":"Nature"},{"key":"BFgt201636_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature11537","volume":"491","author":"VM Bedell","year":"2012","unstructured":"Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG, Krug RG II et al. In vivo genome editing using a high-efficiency TALEN system. Nature 2012; 491: 114\u2013118.","journal-title":"Nature"},{"key":"BFgt201636_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/bfgp\/elu013","volume":"13","author":"R Jankele","year":"2014","unstructured":"Jankele R, Svoboda P . TAL effectors: tools for DNA targeting. Brief Funct Genomics 2014; 13: 409\u2013419.","journal-title":"Brief Funct Genomics"},{"key":"BFgt201636_CR13","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/nar\/gkr976","volume":"40","author":"M Holkers","year":"2012","unstructured":"Holkers M, de Vries AA, Goncalves MA . Nonspaced inverted DNA repeats are preferential targets for homology-directed gene repair in mammalian cells. Nucleic Acids Res 2012; 40: 1984\u20131999.","journal-title":"Nucleic Acids Res"},{"key":"BFgt201636_CR14","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1038\/srep06409","volume":"4","author":"U Mock","year":"2014","unstructured":"Mock U, Riecken K, Berdien B, Qasim W, Chan E, Cathomen T et al. Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Scientific Rep 2014; 4: 6409.","journal-title":"Scientific Rep"},{"key":"BFgt201636_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Z Wu","year":"2006","unstructured":"Wu Z, Asokan A, Samulski RJ . Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316\u2013327.","journal-title":"Mol Ther"},{"key":"BFgt201636_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/hum.2008.123","volume":"19","author":"LT Bish","year":"2008","unstructured":"Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008; 19: 1359\u20131368.","journal-title":"Hum Gene Ther"},{"key":"BFgt201636_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/mt.2011.34","volume":"19","author":"H Fu","year":"2011","unstructured":"Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM . Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood\u2013brain barrier gene delivery. Mol Ther 2011; 19: 1025\u20131033.","journal-title":"Mol Ther"},{"key":"BFgt201636_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14712598.2012.681463","volume":"12","author":"RD Dayton","year":"2012","unstructured":"Dayton RD, Wang DB, Klein RL . The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 2012; 12: 757\u2013766.","journal-title":"Expert Opin Biol Ther"},{"key":"BFgt201636_CR19","doi-asserted-by":"publisher","first-page":"e76310","DOI":"10.1371\/journal.pone.0076310","volume":"8","author":"DF Aschauer","year":"2013","unstructured":"Aschauer DF, Kreuz S, Rumpel S . Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 2013; 8: e76310.","journal-title":"PLoS One"},{"key":"BFgt201636_CR20","first-page":"275","volume-title":"Handbook of Clinical Neurology","author":"M Pandolfo","year":"2012","unstructured":"Pandolfo M . Friedreich ataxia. In: Subramony SH, D\u00fcrr A (eds). Handbook of Clinical Neurology, 3rd edn, vol. 103. Elsevier: Amsterdam, 2012, pp 275\u2013294."},{"key":"BFgt201636_CR21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","volume":"6","author":"V Campuzano","year":"1997","unstructured":"Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997; 6: 1771\u20131780.","journal-title":"Hum Mol Genet"},{"key":"BFgt201636_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","volume":"303","author":"AH Koeppen","year":"2011","unstructured":"Koeppen AH . Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011; 303: 1\u201312.","journal-title":"J Neurol Sci"},{"key":"BFgt201636_CR23","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli C, Soltys S, Rengo G, Rabinowitz JE . Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16: 1073\u20131080.","journal-title":"Mol Ther"},{"key":"BFgt201636_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/mt.2013.188","volume":"22","author":"T Suwanmanee","year":"2014","unstructured":"Suwanmanee T, Hu G, Gui T, Bartholomae CC, Kutschera I, von Kalle C et al. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice. Mol Ther 2014; 22: 567\u2013574.","journal-title":"Mol Ther"},{"key":"BFgt201636_CR25","doi-asserted-by":"publisher","first-page":"16469","DOI":"10.1523\/JNEUROSCI.2440-10.2010","volume":"30","author":"J Laganiere","year":"2010","unstructured":"Laganiere J, Kells AP, Lai JT, Guschin D, Paschon DE, Meng X et al. An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci 2010; 30: 16469\u201316474.","journal-title":"J Neurosci"},{"key":"BFgt201636_CR26","doi-asserted-by":"publisher","first-page":"11163","DOI":"10.1093\/nar\/gks875","volume":"40","author":"AC Mercer","year":"2012","unstructured":"Mercer AC, Gaj T, Fuller RP, Barbas CF III . Chimeric TALE recombinases with programmable DNA sequence specificity. Nucleic Acids Res 2012; 40: 11163\u201311172.","journal-title":"Nucleic Acids Res"},{"key":"BFgt201636_CR27","doi-asserted-by":"publisher","first-page":"e66459","DOI":"10.1371\/journal.pone.0066459","volume":"8","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Li D, Xu H, Xin Y, Zhang T, Ma L et al. A simple and efficient method for assembling TALE protein based on plasmid library. PLoS One 2013; 8: e66459.","journal-title":"PLoS One"},{"key":"BFgt201636_CR28","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1101\/gr.179044.114","volume":"25","author":"LR Polstein","year":"2015","unstructured":"Polstein LR, Perez-Pinera P, Kocak DD, Vockley CM, Bledsoe P, Song L et al. Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR\/Cas9-based transcriptional activators. Genome Res 2015; 25: 1158\u20131169.","journal-title":"Genome Res"},{"key":"BFgt201636_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/mt.2009.15","volume":"17","author":"FP Manfredsson","year":"2009","unstructured":"Manfredsson FP, Rising AC, Mandel RJ . AAV9: a potential blood\u2013brain barrier buster. Mol Ther 2009; 17: 403\u2013405.","journal-title":"Mol Ther"},{"key":"BFgt201636_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neulet.2014.05.044","volume":"576","author":"JR McLean","year":"2014","unstructured":"McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ et al. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett 2014; 576: 73\u201378.","journal-title":"Neurosci Lett"},{"key":"BFgt201636_CR31","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1089\/hum.2010.245","volume":"22","author":"SJ Gray","year":"2011","unstructured":"Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 2011; 22: 1143\u20131153.","journal-title":"Hum Gene Ther"},{"key":"BFgt201636_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/nar\/gkv019","volume":"43","author":"U Muller-Kuller","year":"2015","unstructured":"Muller-Kuller U, Ackermann M, Kolodziej S, Brendel C, Fritsch J, Lachmann N et al. A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Res 2015; 43: 1577\u20131592.","journal-title":"Nucleic Acids Res"},{"key":"BFgt201636_CR33","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest 2015; 125: 870\u2013880.","journal-title":"J Clin Invest"},{"key":"BFgt201636_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1089\/hum.2015.29014.kib","volume":"26","author":"KI Berns","year":"2015","unstructured":"Berns KI, Byrne BJ, Flotte TR, Gao G, Hauswirth WW, Herzog RW et al. Adeno-associated virus type 2 and hepatocellular carcinoma? Hum Gene Ther 2015; 26: 779\u2013781.","journal-title":"Hum Gene Ther"},{"key":"BFgt201636_CR35","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/mt.2011.22","volume":"19","author":"N Pulicherla","year":"2011","unstructured":"Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna M et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 2011; 19: 1070\u20131078.","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"BFgt201636_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jnc.12219","volume":"126","author":"M Perdomini","year":"2013","unstructured":"Perdomini M, Hick A, Puccio H, Pook MA . Animal and cellular models of Friedreich ataxia. J Neurochem 2013; 126 (Suppl 1): 65\u201379.","journal-title":"J Neurochem"},{"key":"BFgt201636_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2014.09.039","volume":"159","author":"ME Tanenbaum","year":"2014","unstructured":"Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD . A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 2014; 159: 635\u2013646.","journal-title":"Cell"},{"key":"BFgt201636_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nbt.3199","volume":"33","author":"IB Hilton","year":"2015","unstructured":"Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 2015; 33: 510\u2013517.","journal-title":"Nat Biotechnol"},{"key":"BFgt201636_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nmeth.3312","volume":"12","author":"A Chavez","year":"2015","unstructured":"Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, PRI E et al. Highly efficient Cas9-mediated transcriptional programming. Nat Methods 2015; 12: 326\u2013328.","journal-title":"Nat Methods"},{"key":"BFgt201636_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2144\/05382RR05","volume":"38","author":"V Luu-The","year":"2005","unstructured":"Luu-The V, Paquet N, Calvo E, Cumps J . Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction. Biotechniques 2005; 38: 287\u2013293.","journal-title":"Biotechniques"},{"key":"BFgt201636_CR41","first-page":"7.35","volume-title":"Molecular Cloning: A Laboratory Manual","author":"MR Green","year":"2001","unstructured":"Green MR, Sambrook J . Northern blotting: Transfer of denatured RNA to membranes. In: Sambrook J, Russell DW (eds). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: : Cold Spring Harbor, NY, USA, 2001, pp 7.35\u20137.41."},{"key":"BFgt201636_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mtm.2014.44","volume":"1","author":"C G\u00e9rard","year":"2014","unstructured":"G\u00e9rard C, Xiao X, Filali M, Coulombe Z, Arsenault M, Couet J et al. An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models. Mol Ther Methods Clin Dev 2014; 1: 1\u201311.","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/gt201636.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gt201636","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gt201636.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:34:18Z","timestamp":1684431258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFgt201636"],"URL":"https:\/\/doi.org\/10.1038\/gt.2016.36","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,5]]},"assertion":[{"value":"22 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JPT is conducting research on gene therapy for Friedreich's ataxia under a research contract with Amorchem Inc. and a patent for such treatment has been applied for by his university. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}